Skip to main content

Phizer Case Proves Disclosure is the Best Policy

July 1, 2013

Mike Fenwick writes for the July/August 2013 issue of Canadian Chemical News discussing a legal decision from the Supreme Court of Canada to invalidate Phizer's patent that protect their drug, Viagara.

To read the article, please click here.

Content shared on Bereskin & Parr’s website is for information purposes only. It should not be taken as legal or professional advice. To obtain such advice, please contact a Bereskin & Parr LLP professional. We will be pleased to help you.

Author(s):

Michael Fenwick Michael Fenwick
B.Sc., M.Sc. (Org. Chem.), LL.B.
Partner
416.957.1665  email Michael Fenwick